All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the real-world experience of R/R AML treatment with venetoclax + HMAs?

During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory AML treatment with venetoclax and hypomethylating agents (HMAs)?

What is the real-world experience of R/R AML treatment with venetoclax + HMAs?

In this video, DiNardo explains how the response rate of this regimen compares to other salvage chemotherapy options. She highlights that patients in the relapse setting have a higher chance of responding to this HMA regimen, including patients with diploid cytogenetics or MPN1, IDH1, and IDH2 mutations.

Share: